Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Soligenix, Inc.    SNGX

SOLIGENIX, INC.

(SNGX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/27/2020 11/30/2020 12/01/2020 12/02/2020 12/03/2020 Date
2.18(c) 2.27(c) 2.24(c) 2.31(c) 2.29(c) Last
225 726 573 866 380 488 265 584 219 829 Volume
+5.83% +4.13% -1.32% +3.12% -0.87% Change
More quotes
Financials (USD)
Sales 2020 2,25 M - -
Net income 2020 -14,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -4,24x
Yield 2020 -
Sales 2021 6,03 M - -
Net income 2021 -10,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,74x
Yield 2021 -
Capitalization 68,4 M 68,4 M -
Capi. / Sales 2020 30,4x
Capi. / Sales 2021 11,3x
Nbr of Employees 16
Free-Float 96,1%
More Financials
Company
Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin... 
More about the company
Notations Surperformance© of Soligenix, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SOLIGENIX, INC.
04:37pSOLIGENIX : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Sub..
AQ
11/25SOLIGENIX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
11/25SOLIGENIX : Zacks SCR Is Bullish On Soligenix, Suggesting 580% Upside; Multiple ..
AQ
11/19Soligenix Sets Up Trifecta For Three Near-Term Potential Catalysts; CiVax(TM)..
AQ
11/17Pfizer and Moderna COVID-19 Vaccine Candidates Are Promising, but Soligenix's..
NE
11/13SOLIGENIX : Announces Recent Accomplishments And Third Quarter 2020 Financial Re..
AQ
11/12SOLIGENIX : Management's Discussion and Analysis OF FINANCIAL CONDITION AND RESU..
AQ
11/11SOLIGENIX : Invited to Present at Upcoming Virtual Investor Conferences
AQ
10/28SOLIGENIX : SGX301 Trial Data Impresses Zacks SCR; Models Suggest a $15 Price Ta..
AQ
10/23SOLIGENIX : Announces Phase 3 FLASH Study Continues to Demonstrate Positive Bene..
AQ
10/23SOLIGENIX : SGX301 Trail Data Impresses In Cycle 3 Patients; Company Is Evaluati..
AQ
10/09SOLIGENIX : to Present at the BIO Investor Forum
AQ
09/24SOLIGENIX : RiVax® Is The Most Advanced Ricin-Toxin Vaccine Platform In The Worl..
AQ
09/21Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercept..
NE
09/18SOLIGENIX, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Yea..
AQ
More news
News in other languages on SOLIGENIX, INC.

- No features available -

More news
Chart SOLIGENIX, INC.
Duration : Period :
Soligenix, Inc. Technical Analysis Chart | SNGX | US8342233074 | MarketScreener
Technical analysis trends SOLIGENIX, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 8,75 $
Last Close Price 2,29 $
Spread / Highest target 555%
Spread / Average Target 282%
Spread / Lowest Target 74,7%
EPS Revisions
Managers
NameTitle
Christopher J. Schaber Chairman, President & Chief Executive Officer
Jonathan L. Guarino Chief Financial Officer, Secretary & Senior VP
Oreola Donini Chief Scientific Officer & Senior Vice President
Richard C. Straube Chief Medical Officer & Senior Vice President
Gregg Anthony Lapointe Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SOLIGENIX, INC.59.31%69
GILEAD SCIENCES, INC.-5.92%76 628
VERTEX PHARMACEUTICALS3.54%58 951
REGENERON PHARMACEUTICALS34.64%53 359
WUXI APPTEC CO., LTD.67.28%39 880
BIONTECH SE257.41%29 157